High-Risk Myeloma
Understanding Genetics and Tailored Treatment
Medical Disclaimer: The following content is compiled based on the latest authoritative guidelines at home and abroad. It is for reference only for patients and their families and cannot replace the professional medical advice of the attending physician. Please be sure to follow the doctor's advice for the treatment plan.
Core Conclusion
High-risk multiple myeloma, defined by cytogenetics like del(17p), t(4;14), or 1q21 affecting 20% to 25% of patients, requires intensive anti-CD38 quadruplets and dual-agent maintenance to extend progression-free survival beyond 3 to 5 years.
Detailed Points
Here is a detailed breakdown of what risk stratification means for you:
(1) High-Risk Genetic Abnormalities and What They Mean Your doctor will perform a bone marrow test (such as FISH or next-generation sequencing) to look at the chromosomes inside your myeloma cells. Chromosomes are the instruction manuals for your cells, and in myeloma, these manuals can get mixed up. Some specific mix-ups (abnormalities) tell us the myeloma might be more aggressive:
- del(17p) and/or TP53 mutation: This means a piece of the short arm of chromosome 17 is missing, or the TP53 gene is mutated. If this abnormality is found in >= 20%$ of your myeloma cells, it is considered high-risk because it can make the myeloma grow faster, be harder to treat, and relapse earlier.
- Translocations—t(4;14), t(14;16), or t(14;20): A "translocation" happens when two chromosomes break and swap pieces. These specific swaps are high-risk, especially when they co-occur with abnormalities on chromosome 1.
- 1q21 Gain or Amplification (+1q): This means the cell has extra copies of the long arm of chromosome 1 (3 copies is a "gain", >= 4 copies is an "amplification"). This change is linked to more aggressive disease and a higher risk of early progression.
- del(1p32): A deletion of a portion of chromosome 1.
- Other High-Risk Blood Markers: Having a high level of a protein called Beta-2 Microglobulin ( β2M >= 5.5 mg/L) alongside normal kidney function (creatinine < 1.2 mg/dL) is also considered a high-risk feature.
- "Double-Hit" Myeloma: If your testing shows two or more of these high-risk genetic abnormalities at the same time, it is referred to as "double-hit" myeloma. This indicates a very high-risk disease that requires the most robust and intensive treatment strategy available.
(2) Core Differences in Treatment Strategies (High-Risk vs. Standard-Risk) If you are identified as high-risk, your medical team will likely use a more aggressive, prolonged treatment approach to keep the disease under control:
- Regimen Choice (Induction Therapy): For newly diagnosed patients, the preferred initial treatment for both standard and high-risk myeloma is often a highly effective 4-drug combination (a "quadruplet" like Daratumumab + Bortezomib + Lenalidomide + Dexamethasone, known as Dara-VRd). However, high-risk patients are strongly encouraged to participate in clinical trials to access the absolute newest therapies.
- ASCT Timing (Stem Cell Transplant): While a single Autologous Stem Cell Transplant (ASCT) is the standard of care for eligible patients, high-risk patients are often recommended to undergo a "Tandem ASCT." This means receiving two back-to-back stem cell transplants within 6 months to achieve the deepest possible clearance of the cancer cells.
- Maintenance Therapy Duration and Drugs:
- Standard-risk patients typically start maintenance therapy roughly 100 days after their transplant using a single oral drug (Lenalidomide/Revlimid).
- High-risk patients may need to start maintenance earlier—around 60 days post-transplant—because preventing a quick relapse is the highest priority. Furthermore, high-risk patients are strongly advised to use "doublet" (two-drug) maintenance, such as Lenalidomide combined with Bortezomib or an anti-CD38 antibody (like Daratumumab), and to continue this continuous therapy until the disease progresses.
Comparison Table: High-Risk vs. Standard-Risk
| Feature | Standard-Risk Myeloma | High-Risk Myeloma |
|---|---|---|
| Genetic Profile | No high-risk genetic changes (e.g., isolated trisomies, t(11;14)). | Presence of del(17p) >= 20%$, TP53 mutation, t(4;14), 1q21 gain/amp, etc.. |
| Induction Therapy | Usually a 3-drug or 4-drug combination (e.g., VRd, Dara-VRd) for ~4 cycles. | Highly aggressive 4-drug combination (e.g., Dara-VRd); clinical trials strongly preferred. |
| Stem Cell Transplant (ASCT) | Single ASCT is standard. | Single ASCT, but Tandem (Double) ASCT should be strongly considered. |
| Maintenance Start Time | Typically begins 100 days after transplant. | May begin as early as 60 days after transplant. |
| Maintenance Drugs | Single-agent therapy (usually Lenalidomide). | Doublet therapy (e.g., Lenalidomide + Bortezomib or Darzalex). |
| Maintenance Duration | Usually continuous, but stopping may be considered if deep remission is achieved. | Continuous treatment is required until the disease progresses or cannot be tolerated. |
The above content is sourced from the following references
- International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
- Mayo Stratification for Myeloma And Risk-adapted Therapy Newly Diagnosed Myeloma
- Mayo Stratification for Myeloma And Risk-adapted Therapy Relapsed Myeloma
- NCCN Guidelines Version 5.2026 Multiple Myeloma
- First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma
- NCCN Guidelines for Patients: Multiple Myeloma
FAQs
- Does high-risk myeloma mean there is no hope?
- No. High risk describes a more stubborn genetic fingerprint, not a lack of treatment options. Modern care uses stronger, tailored plans designed specifically for these more aggressive cell types.
- Which genetic changes are considered high-risk?
- Doctors look at marrow cells with FISH or next-generation sequencing. High-risk findings include del(17p) or a TP53 mutation in 20% or more of myeloma cells, translocations such as t(4;14), t(14;16), or t(14;20), extra copies of 1q21, and del(1p32). A high beta-2 microglobulin of 5.5 mg/L or more with still-normal kidney function is also a high-risk blood marker.
- What is double-hit myeloma?
- Double-hit myeloma means two or more of these high-risk genetic abnormalities are present at the same time. That pattern is treated as very high-risk disease. It usually calls for the most robust, intensive strategy available.
- How is first treatment different for high-risk disease?
- A four-drug combination such as Dara-VRd is often preferred for both standard-risk and high-risk patients. High-risk patients are also strongly encouraged to join clinical trials to reach the newest therapies. Eligible high-risk patients may be offered tandem transplant, meaning two transplants within 6 months.
- How does maintenance differ if I am high-risk?
- Standard-risk patients typically start single-drug lenalidomide about 100 days after transplant. High-risk patients may start around day 60 and usually receive two-drug maintenance, such as lenalidomide plus bortezomib or an anti-CD38 antibody. That combination is continued until the disease progresses or cannot be tolerated.
Related reading
References used for this guide
- International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
- Mayo Stratification for Myeloma And Risk-adapted Therapy Newly Diagnosed Myeloma
- Mayo Stratification for Myeloma And Risk-adapted Therapy Relapsed Myeloma
- NCCN Guidelines Version 5.2026 Multiple Myeloma
- First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma
- NCCN Guidelines for Patients: Multiple Myeloma
Active Trials for High-Risk and Specific Cytogenetic Abnormalities
Innovative targeted therapies and cellular treatments for high-risk or specific cytogenetic profiles:
A Phase II, open-label, single-arm, multicenter clinical study evaluating the efficacy and safety of BCMA-targeted chimeric antigen receptor T-cell injection (CART-BCMA) in patients with relapsed/refractory multiple myeloma (RRMM)
This Phase II study sponsored by Shenzhen Pregene Biopharma Co., Ltd. enrolls patients with relapsed/refractory multiple myeloma who have received at least three prior lines of therapy. Participants receive a single intravenous infusion of a BCMA-targeted CAR-T cell product made from their own modified immune cells. The study is evaluating efficacy and safety at 25 sites in China, including the First Affiliated Hospital, Zhejiang University School of Medicine and Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.
A Phase I Clinical Study Evaluating the Safety and Pharmacokinetics of Subcutaneous Formulation of TQB2934 for Injection in Participants with Malignant Plasma Cell Neoplasms
This project is a Phase I clinical trial sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., primarily enrolling patients with relapsed/refractory multiple myeloma (RRMM) who have previously received at least 1 line of therapy and are refractory to at least 1 proteasome inhibitor (PI), 1 immunomodulatory drug (IMiD), and 1 anti-CD38 monoclonal antibody. The treatment regimen utilizes a novel antitumor biologic, subcutaneous formulation of TQB2934 for injection, administered in 28-day cycles: once weekly in Cycles 1-3 and once every 2 weeks in Cycles 4-6; if partial response (PR) or better is achieved, dosing frequency may be adjusted to once every 4 weeks, with a maximum treatment duration not exceeding 5 years. The trial is conducted at a total of 14 core medical centers in China, including Zhongshan Hospital, Fudan University, Jiangsu Province Hospital, Nanjing Drum Tower Hospital, Nanfang Hospital, Southern Medical University, and Guangdong Provincial People's Hospital.
An Open-Label, Multicenter Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of OriCAR-017 in Participants with Relapsed/Refractory Multiple Myeloma (MERCURY)
This project is a Phase Ib/II clinical trial sponsored by OrigiCell Therapeutics (Shanghai) Co., Ltd., primarily enrolling patients with relapsed/refractory multiple myeloma (RRMM) who have failed prior treatment with at least three regimens of different mechanisms of action (an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody), and have confirmed bone marrow plasma cell membrane GPRC5D expression >= 20%. The treatment regimen employs a GPRC5D-targeted chimeric antigen receptor T-cell (CAR-T) therapy (OriCAR-017) administered as a single intravenous infusion. The trial is currently being conducted across 8 domestic core hematology hospitals in China, including The First Affiliated Hospital, Zhejiang University School of Medicine; Shanghai Tongji Hospital; Jiangsu Province Hospital; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; and Sun Yat-sen University Cancer Center.
A Phase I Clinical Study of CBG002 CAR-T Cell Injection in Patients with Relapsed or Refractory Multiple Myeloma
This is a Phase I clinical trial sponsored by Zhejiang Kangbaiyu Biotechnology Co., Ltd., specifically for patients with relapsed or refractory multiple myeloma. Eligible participants will receive the innovative CBG002 CAR-T cell injection administered via a single intravenous infusion. This study aims to evaluate the safety and tolerability of this cell therapy and to explore the optimal therapeutic dose. Currently, the trial is being conducted across three prominent domestic hospitals, including The First Affiliated Hospital, Zhejiang University School of Medicine.
for their academic support:
for myeloma patients globally